0001654954-17-005710.txt : 20170619 0001654954-17-005710.hdr.sgml : 20170619 20170619181625 ACCESSION NUMBER: 0001654954-17-005710 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170619 FILED AS OF DATE: 20170619 DATE AS OF CHANGE: 20170619 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEISS MICHAEL S CENTRAL INDEX KEY: 0001038977 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 17919470 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVE CITY: NEW YORK STATE: NY ZIP: 10022 4 1 section16.xml FORM-4 X0306 4 2017-06-19 0001001316 TG THERAPEUTICS, INC. TGTX 0001038977 WEISS MICHAEL S 2 GANSEVOORT ST, 9TH FLOOR NEW YORK NY 10014 false true false false CEO and President COMMON STOCK 2017-06-19 4 G false 350000 0.00 D 9795917 D COMMON STOCK (RESTRICTED) 2017-06-19 4 A false 834877 0.00 A 10630794 I See Note 4 Reflects the transfer of 350,000 shares of TG Therapeutics stock to the Weiss Family and Descendants Trust. Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on the date of grant; provided however, if the market capitalization threshold is met prior to June 30, 2018 then the shares shall vest on June 30, 2018. Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. /s/ Michael Weiss 2017-06-19